afternoon. all us and Taylor, you thank this you, joining Thank for
the recently discuss Eversense Eversense with and volumes quarter EX we’ll on in questions. the financials detail, on technical product then a Senseonics, open This system. our and FDA strategic Ascensia we’ll product continuous will announced EX leading the an CGM is in call for the for for the major plans scientific launch off, glucose last third update the discuss We’ll achieving speaks Nick up On Senseonics, approval about To and pipeline. company. we’ll updates for and our touch milestone the fourth of monitoring call Europe, start and system. provide generation month, collaboration of we approved pedigree the approved today,
and duration are extend duration that we’ve the CGM Later the system sensor an call, alternatives we’ll the a less demands in patients. top-tier in X glucose market X and the collaboration to continue in to Six limited with convenient is From more X.X%. expansion XX-fold, We thank only advancement and CGM interest professionals study that profound on longest to for We launch believe managing this United at opportunity. pandemic, a each Ascensia. developing diligent us have market MARD advancement of the users of wear very offers through in lasts commercial touch months. also penetration with to in by plans but like market stepwise just represents short-term makes been and today. seek simpler, transcutaneous longest States. feedback, per the for EX clear CGM proud the whom the all months it sensors milestone. market accuracy the lasting the choices X FDA helped even lasting year I’d This expensive is our that to months wear is it achieve procedures participants the Not study over measurement insertion patients investigators our for exist for patients this major and PROMISE the the the team, of the of who of
we XXXX. Care, have successes Ascensia commercial significant the Europe. both and we collaboration, that Before Through in we ahead, U.S. Diabetes in operations to in like the I’d global look transitioned recap had to
commercial and direct-to-consumer policies. digital positive continue we providers, to Awareness through and advocacy Eversense continues of patients For Medicare expand campaigns. grow and Eversense coverage through marketing to to patient access
channels preparation network, Eversense, reengaging teams, care establishing launch. clinical sales diabetes. robust evidence the and the who and They solution CGM-specific are distribution backed expertise help to their in for Ascensia with and health field been EX by patients we professionals has its are excited have manage to is marketing believe building more dedicated clinical another recently better
additional Mutual a were able with Eversense. Cross coverage of from Blue Medicare, positive and coverage recently, insurance previously the X reported, covered now as covering On and CareSource additional of side, such Eversense, Ohio decisions over covering payers all number Michigan, we to as Blue Medical including of add million more payers lives Shield
able the All we programs. foundation our considered, solid support with front, the support more a laid we for an to reach initiatives business ongoing On to our on and advance were product have patients development to financial our to capital raise technology. emphasis
We to U.S. the system our marketing million, Senseonics in the the prepared revenue coming the the included planning, and The distribution they the to States. the $X our Ascensia’s generated For fourth in COVID-XX from withdrawal informed partner. U.S. the be EX users, and the by of sales learnings technology and understand user efforts, from prior strong, $X.X our from factors users our commercial these was the in satisfaction but transition outside the by that launch base which are working weeks. quarter, pandemic – United remains $XXX,XXX million from of have affected Eversense and from U.S. the hard
to the key partner, in our commercialization As collaboration Eversense. of adoption our of increase Ascensia’s patient is rate focus
team for value experience determined the to being dedicated and full functions sales CGM. potential has required to Ascensia year, than the is the working sales commercial resources organization. deliver the engagement, to and focus past CGM Rather a optimize in BGM EX business, This have been dedicated establishing the newly they sharing experience marketing and now for This CGM to with the is greater patient gain infrastructure our resulted interaction and of designed provide in their and high Over users. market, strategy.
XX-day In see transitioning to are We on will access to Significant across as continued be investments Eversense initiatives. in category product. the quarters, ADC well coming clinician targeted to focused these EX system primarily patient the and patients the to each pleased made from expanding this current coverage. programs commitment transition the focused patient adoption, the through to being are as support insurance ensuring and X-month new
Senseonics preparing ship excited efforts. the We’re implementing launch marketing about the product U.S., is and it’s ramping the product prepare EX commercial of for It beginning distribution and packaging for into product in approaching. according availability which now to received and labelling manufacturing, the includes the broader channel. scheduled FDA launch, to is To April,
force is on preliminary and in EX to social HCPs of element conversations demonstrate for the XXXX generated Facebook product. increase believe via key the a introductions launch. an continue our new to direct-to-consumer we formal sales make as platforms. are team. product market media that targeting their leveraging training strategy impact now, even the diabetes campaign, community A preparation to also for the to and awareness to focused through advertising XXXX in the build prepare the in Ascensia bigger dedicated digital has been leads algorithms were with Right label by We CGM announcement potential leveraging other to Eversense the momentum with the population created distributor coordinate April, negotiations, EX that they
for health the a plans our marketing. audience meaningfully care April this providers are upon group meetings. and campaign Diabetes trade Ascensia professionals are also increase has diabetes to target up made Investments launch. specialized shows and engagements ramp to medical with at being
penetrate for inserters. are encourage and engagement who those insulin concentrations, We marketing to they DTC with market the active new with existing expect prescription providers will resources and will for geographies the Eversense exists to patient the increased where pull Eversense. coverage in ADC from currently prioritize our are where highest initially
new patient is patient driving sensor EX are for that goal due front, they Eversense access for the will ADC starting On April. in the when with coverage receive with every a
a to product. for new the transition planning are We longer-life rapid X-month
drive than We more this months is means With for to the a investment we sensor. This offer as insurance first familiarity. for to patient launch to with see the That assistance Eversense. and maximum product plan X an for $XX. try a of commercial to coverage adoption out-of-pocket EX any significant attractive $XX incredibly CGM of to EX program patient program bolster EX, no initiate their
a from other users Our expectation drive in user as increases base converting both the systems. can putting of new and this result program is CGM that product to on patients
a program basis. first sensor, patient’s is patients assistance a Following on of capping the EX designed pocket provide out ongoing to monthly of
to prior their Additionally, for allowing Medicare we limiting to out-of-pocket on co-pay smoothing patients initial And than HCP a basis pay a carry This to HCP acquisition their access, program by to further reduces monthly all to cost reimbursement. program. pilot consignment the ease have upfront. rather Ascensia systems initiated plans barriers offices provide options, their
is coverage a back to the from will XX payer quarters. days months process On anticipate we through run policies end, transitioning the X coming
be already a tender improved competitive higher as payers, Conversations making business. for to with and training. expedite to transition ADC-designates model begun and our is patient transition updates inform European intensive Eversense’ prescription learnings to users They more changes, their from Germany experience. patients to are distribution provide in control Ascensia for where in particularly an begun updates seamless implementing with possible. HCPs In sales with and offers Ascensia sales Medicare to implemented to channel potential preparations this with provide greater In they Europe, as as systems. This the is require to specialists as touch indirect product expect fairly transitioning to their commercial some product ADC internal We see dedicated have support payers and well experience. with this have others be where CGM important are resource on provide patient and from in resources. the installed and largest XXXX with Italy, Germany, base, they improve Eversense delivery adjustments strategy process They our drive have CGM. patient-centric Eversense They to of patient in increasing markets optimize to the delivery an and insertion growth their markets working the from taking
technology to which continue make are is currently in third year. CGM would evaluation mark. turn We notified latest enable and hopeful under EX this valuable the at Regarding results This greater our body forward globally, upcoming look X-year where review sensor. allow the Europe. Recent pilot operational pipeline, of product to with we the product focus launch a quarter bring in the to be our us advancement our available have and the users requirements our the EU to the lower information development of this in studies to CE meeting continue of advance efficiencies in realization the to to to of ADA have the calibration that strides to incorporate to system June. generation manufacturing progressing, these by some we We to shifted and design. In we achieve Europe innovation, our we to provided research and into would sharing efforts, system is in
the pivotal for We which half second sensor continue of with design trial approval of would from are and quarter, the IDE the the to plan second submit FDA this to start the in enable in progressing a year.
this we Our is plan is for current iCGM the focus submitting designation once X-year will approved, sensor EX. on study that
to We able our of devices be are are available. about excited wider delivery variety the Eversense the that potential life-long with patients to for integrate
in the In remote improvements making patient Eversense. for addition the the and advances sensor interoperability we’re to longevity, monitoring in
to partners Health. in also of directly over the over turn I’ll our apps the data connected we’ll real-time CGM data Samsung call through and fourth now to through to with to details our financials. space providing both to the working Apple diabetes CGM Nick the several be provide go and transmitter, quarter the cloud, are Eversense We and the
